Yanxia Shi

机构：Target (United States), Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China · ORCID：0000-0002-9658-0032

发表论文 54 篇 · 总被引 1153 次 · h-index 15

代表论文

• Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials (2023 · Journal of Clinical Oncology · 被引 168)
• RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials. (2022 · Journal of Clinical Oncology · 被引 33)
• Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment (2024 · Frontiers in Immunology · 被引 25)
• First‐line programmed death receptor‐1 ( PD ‐1) inhibitor and epidermal growth factor receptor (EGFR) blockade, combined with platinum‐based chemotherapy, for stage IV penile cancer (2022 · British Journal of Urology · 被引 22)
• First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors (2022 · Nature Communications · 被引 21)
• Human papillomavirus infection affects treatment outcomes and the immune microenvironment in patients with advanced penile squamous cell carcinoma receiving programmed cell death protein 1 inhibitor–based combination therapy (2023 · Cancer · 被引 16)